艾塞那肽联合二甲双胍治疗2型糖尿病的疗效观察

摘要

Objective:To investigate the clinical efficacy and safety of Exenatide combined with Metformin in the treatment of type 2 diabetes mellitus. Method:67 cases with type 2 diabetes mellitus in our hospital from June 2011 to June 2013 were considered as the observation group and another 34 cases were considered as the control group.The observation group was treated with Exenatide and Metformin,while the control group was treated with Repaglinide.Comparing the clinical efficacy and safety of two groups.Result:16 weeks after the treatment,the observation group hypoglycemic compliance rate rose to 62.69%,the control group rose to 50.00%(P<0.05).After treatment,FPG,HbA1c and BMI in the observation group compared with the control group decreased significantly,P<0.05).The observation group compared with the control group in 2 h PBG was significantly reduced,but the difference was not statistically significant(P>0.05). The observation group compared with the control group,there were significant differences in serum lipids and C peptide index after treatment(P<0.05),the observation group can significantly reduce blood lipids,and elevated serum C peptide index compared with the control group.The incidence of adverse reaction in observation group was 4.48%,the control group was 11.76%,there was no significant difference between two groups(P>0.05).Adverse reactios of two groups with drug withdrawal and symptomatic treatment were improved and disappeared,did not cause adverse consequences.Conclusion:Exenatide can continuously and effectively control blood glucose in type 2 diabetes mellitus.The combined application of exenatide and metformin could reduce patients’ body weight,improve endocrine indexes of patients and reduce the risk of hypoglycemia,it could be considered as a good choice in treatment of type 2 diabetes mellitus,is worthy of clinical application.%目的：观察和探讨艾塞那肽联合二甲双胍治疗2型糖尿病的临床疗效性和安全性。方法：2011年6月-2013年6月就诊于笔者所在医院的2型糖尿病患者67例作为观察组，观察组患者给予艾塞那肽联合二甲双胍进行治疗，同时入选同期于笔者所在医院治疗的2型糖尿病患者34例作为对照组，对照组患者给予瑞格列奈治疗，对两组患者的临床疗效性和安全性进行对比研究。结果：治疗16周后观察组降糖达标率上升至62.69%，对照组上升至50.00%，两组比较差异有统计学意义(P<0.05)；治疗后FPG、HbA1c及BMI方面观察组对比对照组均有显著降低(P<0.05)，观察组对比对照组2 h PBG方面虽有明显降低，但差异无统计学意义(P>0.05)；观察组对比对照组血脂、C肽指标方面治疗后差异有统计学意义(P<0.05)；观察组不良反应发生率为4.48%，对照组为11.76%，两组比较差异有统计学意义(P<0.05)，两组患者不良反应经停药及对症治疗均好转消失，未造成不良后果。结论：艾塞那肽能够持续有效控制2型糖尿病患者血糖情况，与二甲双胍联合应用降糖效果显著，同时有降低患者体质量的优势，改善患者内分泌指标，减低低血糖发生风险，可以成为临床上治疗2型糖尿病的较好选择，值得临床推广应用。